BoneGrafix, a privately held medical device and biomaterials company, has announced that Global Biotech of Wilmington, Del., signed a letter of intent to take a minority stake in BoneGrafix through an equity investment, according to a company news release.
BoneGrafix's focuses on providing solutions for spine and general orthopedics, cosmetic dentistry and cosmetic facial reconstruction. The proceeds of the financing will be used to support the BoneGrafix's commercialization efforts for its portfolio of regenerative bone products.
"We are pleased with the support and recognition by Global Biotech and look forward to their continued support as BoneGrafix achieves a leadership role in regenerative medicine for bone replacement," said George Steinfels, chairman and CEO of BoneGrafix.
Read the company news release about BoneGrafix.
Read other coverage about device companies:
- MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
- Exactech Announces 4Q Revenue of $51.8M, 7% Increase
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease
BoneGrafix's focuses on providing solutions for spine and general orthopedics, cosmetic dentistry and cosmetic facial reconstruction. The proceeds of the financing will be used to support the BoneGrafix's commercialization efforts for its portfolio of regenerative bone products.
"We are pleased with the support and recognition by Global Biotech and look forward to their continued support as BoneGrafix achieves a leadership role in regenerative medicine for bone replacement," said George Steinfels, chairman and CEO of BoneGrafix.
Read the company news release about BoneGrafix.
Read other coverage about device companies:
- MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
- Exactech Announces 4Q Revenue of $51.8M, 7% Increase
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease